10 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck's Birchview Capital. Matthew Strobeck earned his Ph.D.
Acceleron Pharma Inc (XLRN)
This company is not actively trading or the ticker does belong to another company in our database now.
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | BAMCO Inc. Ron Baron | 0 | $0 | 0% | |
| 2. | Olympiad Research LP Thong Nguyen | 0 | $0 | 0% | |
| 3. | Shay Capital Samuel Ginzburg | 0 | $0 | 0% | |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% | |
| 5. | Walleye Capital Will England | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $92.50 | 108,108 | $9,999,990.00 | 6,971,772 | 2020-07-01 | Filing | |
| $38.05 | 5,000 | $190,250.00 | 12,750 | 2019-06-14 | Filing | |
| $43.00 | 706,206 | $30,366,858.00 | 6,824,685 | 2019-01-18 | Filing | |
| $37.00 | 745,592 | $27,586,904.00 | 6,118,479 | 2017-09-25 | Filing | |
| $25.50 | 4,000 | $102,000.00 | 4,000 | 2016-12-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $175.00 | 5,000 | $875,000.00 | 18,509 | 2021-09-27 | Filing | |
| $160.38 | 5,370 | $861,240.60 | 10,681 | 2021-09-24 | Filing | |
| $161.26 | 983 | $158,518.58 | 10,681 | 2021-09-23 | Filing | |
| $160.26 | 18,647 | $2,988,368.22 | 11,664 | 2021-09-23 | Filing | |
| $150.05 | 6,650 | $997,832.50 | 18,923 | 2021-09-21 | Filing |
Institutional Investors' Holdings
News See All
Here's Why You Should Consider Investing in Acceleron Pharma (XLRN)
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
Analysts are Raising Price Targets of These 10 Stocks
In this article, we discuss the 10 stocks that analysts are raising price targets of.
Baron Funds: "Acceleron (XLRN) Remains a Top Pick, We Have Not Changed Our Conviction"
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson
In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson.
15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US.
Is Acceleron Pharma (XLRN) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here.
Is Acceleron Pharma Inc (XLRN) A Good Stock To Buy?
Is Acceleron Pharma Inc (NASDAQ:XLRN) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research.
Former CEO of Finish Line Inc. (FINL) Sells Shares as Underperformance Persists; Other Notable Insider Transactions
It is already common knowledge that corporate insiders are savvy long-term-oriented investors, with their purchases beating broader market benchmarks on aggregate.
Hedge Funds Are Buying Acceleron Pharma Inc (XLRN)
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively...